Equity Overview
Price & Market Data
Price: $3.37
Daily Change: -$0.015 / 0.45%
Daily Range: $3.36 - $3.57
Market Cap: $437,153,376
Daily Volume: 1,222,344
Performance Metrics
1 Week: 9.58%
1 Month: -13.02%
3 Months: -14.77%
6 Months: -15.84%
1 Year: -8.04%
YTD: -6.51%
Company Details
Employees: 57
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.